In This Article:
A month has gone by since the last earnings report for CRISPR Therapeutics AG (CRSP). Shares have added about 0.4% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is CRISPR Therapeutics due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
How Have Estimates Been Moving Since Then?
It turns out, fresh estimates have trended downward during the past month.
The consensus estimate has shifted 8.37% due to these changes.
VGM Scores
Currently, CRISPR Therapeutics has a poor Growth Score of F, however its Momentum Score is doing a lot better with a B. However, the stock was allocated a grade of F on the value side, putting it in the fifth quintile for this investment strategy.
Overall, the stock has an aggregate VGM Score of F. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions looks promising. Notably, CRISPR Therapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
Performance of an Industry Player
CRISPR Therapeutics belongs to the Zacks Medical - Biomedical and Genetics industry. Another stock from the same industry, Astrazeneca (AZN), has gained 1.5% over the past month. More than a month has passed since the company reported results for the quarter ended December 2024.
Astrazeneca reported revenues of $14.89 billion in the last reported quarter, representing a year-over-year change of +23.8%. EPS of $1.05 for the same period compares with $0.73 a year ago.
Astrazeneca is expected to post earnings of $1.10 per share for the current quarter, representing a year-over-year change of +6.8%. Over the last 30 days, the Zacks Consensus Estimate has changed +1%.
The overall direction and magnitude of estimate revisions translate into a Zacks Rank #4 (Sell) for Astrazeneca. Also, the stock has a VGM Score of B.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
CRISPR Therapeutics AG (CRSP) : Free Stock Analysis Report
AstraZeneca PLC (AZN) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).